GlassScriptPhysician profile
Andrew M Holt
NPI 1144608118
$46,261.84
in general payments reported to CMS, 2019-2025
16 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31K · 2021: $11K · 2022: $159 · 2023: $2,169 · 2024: $2,075 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,254 · Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,253.68 |
| Food and Beverage | $1,135.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $22,712.34 | 2020-2024 | |
| Smith+Nephew, INC. | $19,596.17 | 2020-2021 | |
| Alon Medical Technology | $1,260.29 | 2020 | |
| Alpha Orthopedic Systems | $955.83 | 2023 | |
| Smoky Mountain Surgical LLC | $769.61 | 2024 | |
| Stryker Corporation | $355.21 | 2020-2021 | |
| Glaxosmithkline, LLC. | $197.09 | 2022-2025 | Nucala |
| United Therapeutics Corporation | $112.82 | 2022-2023 | Orenitram, Tyvaso |
| Genzyme Corporation | $73.68 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.06 | 2024-2025 | Airsupra, Breztri |
| Mylan Specialty L.P. | $43.13 | 2022-2024 | Yupelri |
| Abbvie INC. | $41.24 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.59 | 2022 | |
| Genentech USA, INC. | $19.52 | 2025 | Xolair |
| Vertex Pharmaceuticals Incorporated | $17.72 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $16.54 | 2023 | Biobrace 23mm, Linvatec Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.